- Home
- GYRE vs KRP Comparison
GYRE vs KRP Comparison
Compare GYRE & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- KRP
- Stock Information
- Founded
- GYRE 2002
- KRP 2013
- Country
- GYRE United States
- KRP United States
- Employees
- GYRE N/A
- KRP N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- KRP Oil & Gas Production
- Sector
- GYRE Health Care
- KRP Energy
- Exchange
- GYRE Nasdaq
- KRP Nasdaq
- Market Cap
- GYRE 1.2B
- KRP 1.3B
- IPO Year
- GYRE N/A
- KRP 2017
- Fundamental
- Price
- GYRE $12.50
- KRP $15.19
- Analyst Decision
- GYRE
- KRP Strong Buy
- Analyst Count
- GYRE 0
- KRP 5
- Target Price
- GYRE N/A
- KRP $20.20
- AVG Volume (30 Days)
- GYRE 43.7K
- KRP 372.9K
- Earning Date
- GYRE 08-13-2024
- KRP 10-31-2024
- Dividend Yield
- GYRE N/A
- KRP 11.06%
- EPS Growth
- GYRE N/A
- KRP N/A
- EPS
- GYRE N/A
- KRP 0.49
- Revenue
- GYRE $111,587,000.00
- KRP $321,860,199.00
- Revenue This Year
- GYRE $25.32
- KRP $20.29
- Revenue Next Year
- GYRE $12.95
- KRP $6.82
- P/E Ratio
- GYRE N/A
- KRP $31.26
- Revenue Growth
- GYRE N/A
- KRP 25.54
- 52 Week Low
- GYRE $4.80
- KRP $14.26
- 52 Week High
- GYRE $30.40
- KRP $17.11
- Technical
- Relative Strength Index (RSI)
- GYRE 50.86
- KRP 31.06
- Support Level
- GYRE $11.38
- KRP $15.71
- Resistance Level
- GYRE $13.90
- KRP $16.02
- Average True Range (ATR)
- GYRE 1.20
- KRP 0.24
- MACD
- GYRE 0.05
- KRP -0.05
- Stochastic Oscillator
- GYRE 39.51
- KRP 11.01
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.